Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Characterization of cell-free circulating DNA in plasma in patients with prostate cancer.

Delgado PO, Alves BC, Gehrke Fde S, Kuniyoshi RK, Wroclavski ML, Del Giglio A, Fonseca FL.

Tumour Biol. 2013 Apr;34(2):983-6. doi: 10.1007/s13277-012-0634-6. Epub 2012 Dec 27.

PMID:
23269609
2.

Quantitative analysis of plasma cell-free DNA and its DNA integrity in patients with metastatic prostate cancer using ALU sequence.

Fawzy A, Sweify KM, El-Fayoumy HM, Nofal N.

J Egypt Natl Canc Inst. 2016 Dec;28(4):235-242. doi: 10.1016/j.jnci.2016.08.003. Epub 2016 Sep 12.

3.

Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators.

Ellinger J, Bastian PJ, Haan KI, Heukamp LC, Buettner R, Fimmers R, Mueller SC, von Ruecker A.

Int J Cancer. 2008 Jan 1;122(1):138-43.

4.

Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.

Ellinger J, Müller DC, Müller SC, Hauser S, Heukamp LC, von Ruecker A, Bastian PJ, Walgenbach-Brunagel G.

Urol Oncol. 2012 Jul-Aug;30(4):509-15. doi: 10.1016/j.urolonc.2010.03.004. Epub 2010 Sep 26.

PMID:
20870429
5.

Free circulating DNA as a biomarker of prostate cancer: comparison of quantitation methods.

Ramachandran K, Speer CG, Fiddy S, Reis IM, Singal R.

Anticancer Res. 2013 Oct;33(10):4521-9.

PMID:
24123025
6.

Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.

Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B, Eisenberger MA, Partin AW, Nelson WG.

Clin Cancer Res. 2005 Jun 1;11(11):4037-43.

7.

Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection.

Maragh S, Veltri RW, Lund SP, Mangold L, Isharwal S, Christudass CS, Partin AW, Humphreys EB, Sorbara L, Srivastava S, Wagner PD.

Cancer Biomark. 2015;15(6):763-73. doi: 10.3233/CBM-150518.

PMID:
26406418
8.

Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease.

Gordian E, Ramachandran K, Reis IM, Manoharan M, Soloway MS, Singal R.

Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1984-91. doi: 10.1158/1055-9965.EPI-10-0287. Epub 2010 Jul 20.

9.

Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.

Agostini M, Pucciarelli S, Enzo MV, Del Bianco P, Briarava M, Bedin C, Maretto I, Friso ML, Lonardi S, Mescoli C, Toppan P, Urso E, Nitti D.

Ann Surg Oncol. 2011 Sep;18(9):2461-8. doi: 10.1245/s10434-011-1638-y. Epub 2011 Mar 17.

PMID:
21416156
10.

Plasma cell-free DNA and its DNA integrity as biomarker to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate-specific antigen.

Feng J, Gang F, Li X, Jin T, Houbao H, Yu C, Guorong L.

Int Urol Nephrol. 2013 Aug;45(4):1023-8. doi: 10.1007/s11255-013-0491-2. Epub 2013 Jun 19.

PMID:
23779229
11.

Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.

Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5361-7.

12.

The potential use of cell-free-circulating-tumor DNA as a biomarker for prostate cancer.

He WS, Bishop KS.

Expert Rev Mol Diagn. 2016 Aug;16(8):839-52. doi: 10.1080/14737159.2016.1197121. Epub 2016 Jun 20. Review.

PMID:
27254598
13.

Quantitative analysis of free-circulating DNA in plasma of patients with resectable NSCLC.

Szpechcinski A, Chorostowska-Wynimko J, Kupis W, Maszkowska-Kopij K, Dancewicz M, Kowalewski J, Orlowski T.

Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S3-9. doi: 10.1517/14712598.2012.668519. Epub 2012 May 5.

PMID:
22559166
15.

Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer.

Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, Pantel K.

Clin Cancer Res. 2009 Feb 1;15(3):1032-8. doi: 10.1158/1078-0432.CCR-08-1910.

16.

Cell-free DNA and RNA in plasma as a new molecular marker for prostate cancer.

Papadopoulou E, Davilas E, Sotiriou V, Koliopanos A, Aggelakis F, Dardoufas K, Agnanti NJ, Karydas I, Nasioulas G.

Oncol Res. 2004;14(9):439-45.

PMID:
15490975
17.

Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.

Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS.

Clin Chem. 2006 Jun;52(6):1062-9.

18.

Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.

Rouprêt M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM, Phillips J, Meuth M, Cussenot O, Hamdy FC.

Int J Cancer. 2008 Feb 15;122(4):952-6.

19.

The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer.

Ellinger J, Müller SC, Stadler TC, Jung A, von Ruecker A, Bastian PJ.

Urol Oncol. 2011 Mar-Apr;29(2):124-9. doi: 10.1016/j.urolonc.2009.05.010. Epub 2009 Sep 17. Review.

PMID:
19762255
20.

DNA-based detection of prostate cancer in blood, urine, and ejaculates.

Goessl C, Müller M, Heicappell R, Krause H, Miller K.

Ann N Y Acad Sci. 2001 Sep;945:51-8.

PMID:
11708494

Supplemental Content

Support Center